¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ & p  
}c,}V  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© XPXIg  
oGnSPI5KGC  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© [6Izlh+D  
]nn98y+  
1.Co-stimulators (or co-stimulating molecules) 'x#~'v*  
>C>.\  
2.NK-kB C`hU]  
,wb:dj-  
3.Immunoglobulin superfamily g*AWE,%=|  
yLvDMPj  
4.antigen-presenting cell (APC) ;WQve_\  
_`j7clEz  
5.death domain n:?a$Ldgm  
`r6,+&  
6.CCR and CXCR W' VslZG  
^}=,g  
7.Lectin (or mitogen) b4 6~?*  
kS);xA8s]  
8.Clusters of differentiation, CD) "%w u2%i  
k 1~&x$G  
9.B7 family ydA8wL  
)*J^K?!S  
10.Cytotoxic T lymphocyte, CTL) Q(?#'<.#  
aeJ HMHFc  
11.IL-15 and IL-15 receptor (IL-15R) r q].UCj  
T.BW H2gRP  
12.MHC restriction UB@+c k  
V b?oJhR  
13.Affinity-chromatography N~)_DjQP5  
yR{3!{r3(  
14.Cyctosprin A, CsA ^hM4j{|&M  
<\^8fn   
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) sDlO#  
%7.30CA|#  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© {JMVV_}n  
gjDHo$  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 eD6fpe\ (  
!%c\N8<>GD  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 2c*GuF9(0  
s.C_Zf~3  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ UZ+<\+q3^  
[7Oe3=  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© _w +Qy.  
(*iHf"=\  
ÃâÒßѧרҵ£º l]8uk^E  
wnC81$1l~  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ vr =#3>  
g}c~:p  
Ïû»¯ÄÚ¿Æ£º (9dl(QSd  
zTU0HR3A  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ ZJiG!+-j  
E7hY8#G  
ѪҺ²¡Ñ§×¨Òµ£º o66}yJzmD  
8Zd]wYO  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»